RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152

Ronckers, Cecile M.; Tytgat, Lieve; van den Heuvel-Eibrink, Marry M.; Teepen, Jop; Kremer, Leontine C M; Clement, Sarah; van Santen, Hanneke M.

doi:https://doi.org/10.1016/j.ejca.2017.02.019

RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152

Files

risk.pdf (368.91 KB)

Publication date

2017-05

Authors

Ronckers, C.M.

Tytgat, G. A.M.

van den Heuvel-Eibrink, Marry M

Teepen, Jop

Kremer, Leontine C M

Clement, Sarah

Van Santen, Hanneke M.

DOI

https://doi.org/10.1016/j.ejca.2017.02.019

Document Type

Comment

Metadata

Show full item record

Collections

UMC Repository

License

taverne

Keywords

Taverne, Oncology, Cancer Research, Letter

Citation

Ronckers, C M, Tytgat, L, van den Heuvel-Eibrink, M M, Teepen, J, Kremer, L C M, Clement, S & van Santen, H M 2017, 'RE : Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131 -I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152', European Journal of Cancer, vol. 77, pp. 21-23. https://doi.org/10.1016/j.ejca.2017.02.019

URI

https://dspace.library.uu.nl/handle/1874/349218